… The discovery of the epidermal growth factor receptor (EGFR) and development of targeted
… EGFR belongs to the HER/ErbB family of growth factor receptors. These receptors consist of …

Objective To compare the efficacy and safety of first line treatments for patients with advanced
epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer (NSCLC). …

… Epidermal growth factor receptor (EGFR) mutations are the second most … mutations (exon
19 deletions and the L858R point mutation) comprise the vast majority of EGFR mutations and …

PURPOSE In this phase I study (BLOOM), osimertinib, a third-generation epidermal growth
factor receptor (EGFR) tyrosine kinase inhibitor (TKI), was evaluated in patients with …

… Particularly, evidence is accumulating regarding the synergistic association between
metformin and epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitors (TKIs). …

… growth factor receptor (FGFR) family of receptor tyrosine kinases consists of four transmembrane
receptors, … Extensive in vitro and in vivo analyses of these mutations have revealed that …

… Activating mutations can lead to receptor dimerization in the absence of activating ligands,
resulting in constitutive activation of the kinase and the promotion of tumour growth via …

… growth factor receptor (EGFR) mutations are the most common targetable driver mutations …
In patients with EGFR mutations, progression-free survival (PFS) improves after treatment with …

… , these mutations are still associated with driver genes that have prognostic importance in
lung cancer. Since 2004, epidermal growth factor receptor (EGFR) mutations have received …

… Activating mutations in the epidermal growth factor receptor (EGFR) gene have been
identified as oncogenic driver mutations in approximately 15% of lung adenocarcinoma (LUAD) …